# US 2012/0251586 A1 · Ligand-specific inhibition of attachment of immune cells to implantable biomaterials

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251586 A1
- Document ID: US20120251586A1
- Status: Published application
- Kind: A1
- Application number: 13/262,367
- Filed: 2010-04-09
- Published: 2012-10-04
- Earliest claimed: 2009-04-09
- Assignees: The Children's Hospital of Philadelphia
- Inventors: Stanley J. Stachelek; Dennis Discher; Robert J. Levy; Richard Tsai
- Web page: https://patentgrep.com/patent/US20120251586A1

## CPC

- A61L 31/10: Macromolecular materials
- A61L 27/34: Macromolecular materials
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 31/022: {Metals or alloys}
- A61L 31/048: {obtained by reactions only involving carbon-to-carbon unsaturated bonds (A61L31/041 takes precedence)}
- A61L 33/128: {Other specific proteins or polypeptides not covered by A61L33/122 - A61L33/126}
- A61L 2300/252: Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
- A61L 2300/432: Inhibitors, antagonists (A61L2300/402 - A61L2300/43 take precedence)
- A61L 2300/606: Coatings
- A61L 2300/802: Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)

## Abstract

Methods for protecting biomaterials comprise attaching CD47 or Ig domain thereof to the surface of the biomaterial, thereby inhibiting or reducing immune cell attachment and/or immune cell-mediated damage to the biomaterial. Also provided are kits for practicing these methods and the protected biomaterials.

## Claims

### Claim 1

A method for protecting a biomaterial, comprising attaching CD47 or Ig domain thereof to the surface of the biomaterial, wherein the CD47 or Ig domain thereof inhibits or reduces immune cell-mediated damage to the biomaterial.

### Claim 2 (depends on 1)

The method of claim 1, wherein the biomaterial comprises a polymer.

### Claim 3 (depends on 2)

The method of claim 2, wherein the polymer is a polypropylene, polyethylene, polystyrene, polymethylmethacrylate, polyurethane, polyfluorotetraethylene, or polyvinyl, or mixtures thereof.

### Claim 4 (depends on 2)

The method of claim 2, wherein the polymer is polyurethane.

### Claim 5 (depends on 2)

The method of claim 2, wherein the polymer is polyvinyl chloride.

### Claim 6 (depends on 1)

The method of claim 1, wherein the biomaterial is on the surface of an implant.

### Claim 7 (depends on 1)

The method of claim 1, wherein the biomaterial is on the surface of a medical device.

### Claim 8 (depends on 1)

The method of claim 1, wherein the biomaterial is on the surface of a tube.

### Claim 9 (depends on 1)

The method of claim 1, wherein the biomaterial is on the surface of a therapeutic agent delivery vehicle.

### Claim 10 (depends on 6)

The method of claim 6, wherein the implant comprises the biomaterial.

### Claim 11 (depends on 6)

The method of claim 6, wherein the implant is coated with the biomaterial.

### Claim 12 (depends on 7)

The method of claim 7, wherein the medical device comprises the biomaterial.

### Claim 13 (depends on 7)

The method of claim 7, wherein the medical device is coated with the biomaterial.

### Claim 14 (depends on 8)

The method of claim 8, wherein the tube comprises the biomaterial.

### Claim 15 (depends on 8)

The method of claim 8, wherein the tube is coated with the biomaterial.

### Claim 16 (depends on 9)

The method of claim 9, wherein the therapeutic agent delivery vehicle comprises the biomaterial.

### Claim 17 (depends on 9)

The method of claim 9, wherein the therapeutic agent delivery vehicle is coated with the biomaterial.

### Claim 18 (depends on 1)

The method of claim 1, wherein the CD47 or Ig domain thereof inhibits or reduces immune cell-mediated damage to the biomaterial in vitro.

### Claim 19 (depends on 1)

The method of claim 1, wherein the CD47 or Ig domain thereof inhibits or reduces immune cell-mediated damage to the biomaterial in vivo.

### Claim 20 (depends on 1)

The method of claim 1, wherein the surface of the biomaterial comprises at least one linking molecule.

### Claim 21 (depends on 20)

The method of claim 20, wherein the linking molecule is avidin.

### Claim 22 (depends on 20)

The method of claim 20, wherein the linking molecule comprises a thiol.

### Claim 23 (depends on 20)

The method of claim 20, wherein the linking molecule is folate.

### Claim 24 (depends on 20)

The method of claim 20, wherein the linking molecule is the folate receptor.

### Claim 25 (depends on 1)

The method of claim 1, wherein the CD47 or Ig domain thereof is complexed with a linking molecule.

### Claim 26 (depends on 25)

The method of claim 25, wherein the linking molecule is SPDP or SMCC.

### Claim 27 (depends on 25)

The method of claim 25, wherein the linking molecule is folate.

### Claim 28 (depends on 25)

The method of claim 25, wherein the linking molecule is the folate receptor.

### Claim 29 (depends on 1)

The method of claim 1, wherein the linking molecule is biotin.

### Claim 30 (depends on 1)

The method of claim 1, wherein the immune cell expresses SIRP-α.

### Claim 31 (depends on 1)

The method of claim 1, wherein the immune cell is a monocyte or macrophage.

### Claim 32 (depends on 1)

The method of claim 1, wherein the damage is oxidative damage or inflammatory damage.

### Claim 33 (depends on 6)

The method of claim 6, wherein the implant is a pacemaker lead.

### Claim 34 (depends on 8)

The method of claim 8, wherein the tube is part of a heart-lung bypass.

### Claim 35 (depends on 1)

A kit for protecting a biomaterial, comprising CD47 or Ig domain thereof and instructions for using the kit according to the method of claim 1.

### Claim 36 (depends on 35)

The kit of claim 35, further comprising a linking molecule capable of being attached to the surface of the biomaterial.

### Claim 37 (depends on 35)

The kit of claim 35, further comprising a linking molecule capable of being attached to the CD47 or Ig domain thereof.

### Claim 38 (depends on 36)

The kit of claim 36, wherein the linking molecule is avidin.

### Claim 39 (depends on 36)

The kit of claim 36, wherein the linking molecule is the folate receptor.

### Claim 40 (depends on 37)

The kit of claim 37, wherein the linking molecule is biotin.

### Claim 41 (depends on 38)

The kit of claim 38, wherein the linking molecule is SPDP or SMCC.

### Claim 42 (depends on 38)

The kit of claim 38, wherein the linking molecule is folate.

### Claim 43 (depends on 35)

The kit of claim 35, wherein the CD47 or Ig domain thereof is complexed with SPDP or SMCC.

### Claim 44 (depends on 35)

The kit of claim 35, wherein the CD47 or Ig domain thereof is complexed with biotin.

### Claim 45 (depends on 35)

The kit of claim 35, wherein the CD47 or Ig domain thereof is complexed with folate.

### Claim 46

A method for inhibiting or reducing immune cell attachment to a biomaterial, comprising attaching CD47 or Ig domain thereof to the surface of the biomaterial, wherein the CD47 or Ig domain thereof inhibits or reduces immune cell attachment to the biomaterial.

### Claim 47 (depends on 46)

The method of claim 46, wherein the biomaterial comprises a polymer.

### Claim 48 (depends on 47)

The method of claim 47, wherein the polymer is polyurethane.

### Claim 49 (depends on 47)

The method of claim 47, wherein the polymer is polyvinyl chloride.

### Claim 50 (depends on 46)

The method of claim 46, wherein the immune cell expressed SIRP-α.

### Claim 51 (depends on 46)

The method of claim 46, wherein the immune cell is a monocyte or macrophage.

### Claim 52 (depends on 1)

The method of claim 1, wherein the immune cell is a polymorphonuclear leukocyte.

### Claim 53 (depends on 52)

The method of claim 52, wherein the polymorphonuclear leukocyte is a neutrophil.

### Claim 54 (depends on 46)

The method of claim 46, wherein the immune cell is a polymorphonuclear leukocyte.

### Claim 55 (depends on 54)

The method of claim 54, wherein the polymorphonuclear leukocyte is a neutrophil.

### Claim 56

A biomaterial comprising CD47 or Ig domain thereof attached to the surface of the biomaterial.

### Claim 57 (depends on 56)

The biomaterial of claim 56, further comprising at least one linking molecule on the surface of the biomaterial.

### Claim 58 (depends on 57)

The biomaterial of claim 57, wherein the at least one linking molecule mediates the attachment of the CD47 or Ig domain thereof to the surface.
